Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586833 | 0.92 | IDO1 (0.36) | IDO1LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1314001 | 0.88 | AGXT (0.42) | IDO1LMNASMN1; SMN2L3MBTL1MAOB | |
| SCHEMBL5561672 | 0.86 | IDO1 (0.41) | IDO1LMNASMN1; SMN2MAOBHTT | |
| SCHEMBL9472699 | 0.86 | IDO1 (0.37) | IDO1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL11934179 | 0.85 | TP53 (0.42) | IDO1SMN1; SMN2RAB9AL3MBTL1MEN1 | |
| SCHEMBL9347235 | 0.85 | ESR1 (0.43) | IDO1LMNAMEN1KMT2ATP53 | |
| SCHEMBL14542685 | 0.85 | AGXT (0.43) | IDO1LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2466725 | 0.84 | PPARA (0.39) | SMN1; SMN2HTT | |
| SCHEMBL2745018 | 0.84 | PPARG (0.41) | KMT2ATSHRNPSR1 | |
| SCHEMBL9347236 | 0.84 | AGXT (0.33) | IDO1SMN1; SMN2MAOBTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3976608-B1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230078112-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3976608-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243459-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| EP-1453496-A4 | COMPOSITION AND METHOD FOR MODULATING BAR/FXR RECEPTOR ACTIVITY | ALLERGAN INC (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1362855-B1 | BETA-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-7045515-B2 | β-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-16 | — | — | US | disclosed |
| EP-1185277-B1 | Use of FXR synthetic ligands for the treatment of diseseas linked to cholesterol imbalance and colon cancer | ALLERGAN INC (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-1995003700-A1 | BRIDGED BIPHENYL CARBAPENEM ANTIBACTERIAL COMPOUNDS | MERCK & CO., INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| WO-1995003290-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1995-02-02 | — | — | WO | disclosed |
| US-5384317-A | Bactericides | MERCK & CO., INC. (US) | 1995-01-24 | — | — | US | disclosed |
| WO-1994028719-A1 | BRIDGED CARBAPENEM ANTIBACTERIAL COMPOUNDS | MERCK & CO., INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994028718-A1 | BRIDGED CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MERCK & CO., INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5372993-A | Bridged carbapenem compounds, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 1994-12-13 | — | — | US | disclosed |
| US-5338875-A | Boron containing intermediates useful in the preparation of carbapenems | MERCK & CO., INC. (US) | 1994-08-16 | — | — | US | disclosed |
| WO-1994011372-A1 | PREPARATION OF 2-ARYL CARBAPENEMS VIA A BORONIC ACID COUPLING REACTION | MERCK & CO., INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994005634-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-03-17 | — | — | WO | disclosed |
| US-5192758-A | Antibiotics | MERCK & CO., INC. (US) | 1993-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | IDO1 3942/4885LMNA 1109/4885SMN1; SMN2 4185/4885 |
| US-20230078112-A1 | THIADIAZOLYL DERIVATIVES | POLQ, POLK, POLA1 | IDO1 3805/4885LMNA 2130/4885SMN1; SMN2 3104/4885 |
| US-12509454-B2 | Thiadiazolyl derivatives | POLD1, POLQ, DNA2 | IDO1 3800/4885LMNA 2322/4885SMN1; SMN2 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.